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ABSTRACT 
A time-course study was performed to assess lung concentrations and bioactivities of a 
fully  human  monoclonal  antibody  (mAb)  targeting  Pseudomonas  aeruginosa  (PA) 
flagella type b (LST-007) following intra-nasal administration. Intra-nasal administration 
of  LST-007  (5  mg/kg)  resulted  in  high  mAb  concentrations  (11  µg/ml)  within  the 
bronchoalveolar lavage (BAL) fluid at 15 min post-administration, which decreased to    
3 µg/ml at 4 hr. In marked contrast, LST-007 concentrations in blood were 110 and 11 
fold  lower  at  the  same  time  points.  Scrutinization  of  BAL  fluid  demonstrated  the 
presence of both intact and immunoreactive LST-007 towards PAO1 bacteria, which 
impeded bacterial motility, underscoring the maintenance of biological activity. These 
compelling data lay credence that intra-nasal and thus potential inhalation modes of 
administration might represent bona fide routes for a targeted mAb delivery to the lung 
environment  and  establishment  of  therapeutically  effective  concentrations.  Such 
delivery approaches could help combat life-threatening, pneumonia infections caused 
by PA.         
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INTRODUCTION 
 
The  ESKAPE
1  group  of  pathogens  has  been 
identified  as  an  extremely  worrisome  set  of 
bacteria which can stretch the clinician’s drug 
armamentarium due to the capability of these 
bacteria  to  develop  Multi-Drug  Resistant 
(MDR)  phenotypes.  The  “P”  component  of 
ESKAPE,  namely  Pseudomonas  Aeruginosa 
(PA),  a  Gram-negative  bacterium,  is  a  major 
cause of a variety of nosocomial infections of 
which  pneumonia  (hospital  and  ventilator-
associated)  and  urinary  tract  infections 
represent  major  components
2-4.  A  major 
problem associated with infections caused by 
PA is due to the bacterium’s agility to develop 
MDR  phenotypes
5.  This  underscores  the 
urgent  clinical  need  not  only  to  develop 
innovative anti-PA therapeutic strategies which 
can retain activity towards MDR PA strains but 
also the need to develop novel and applicable 
routes of drug administration for new and even 
commonly  used  antibiotics
6.  Such  all  round 
research and development efforts could allow a 
rapid attainment of therapeutically active drug 
concentrations  at  target  tissues  thereby 
potentially  interrupting  the  development  of 
MDR phenotypes. We have recently reported
7 
the  characterization  of  a  fully  human  mAb 
termed LST-007, which targets flagellin type b, 
a  critically-important PA  virulence factor. In  a 
lethal mouse model of acute pneumonia driven 
by a PA isolate resistant to 19/21 antibiotics, 
i.v.  administration  of  LST-007  afforded  a 
significant  improvement  in  survival,  which 
outweighed  the  minimal  improvement  
observed  with  a  carbapenem  antibiotic.  In 
contrast with the anticipated PK profile of LST-
007  in  blood,  analysis  of  the  BAL  fluid 
compartment following a single i.v. injection of 
LST-007  revealed  that  optimal  mAb 
concentrations  were  achieved  only  at  24  hr 
post  mAb  administration
7.  Consequently, 
further beneficial effects of LST-007 might be 
harnessed if its bioactive concentration in lungs 
could be achieved more rapidly following  
 
administration.  To  that  end,  with  our  overall 
intent to embark on further in-vivo PA efficacy 
studies  with  LST-007  and  additional  anti-
flagella  mAbs,  we  wanted  to  address  the 
question  if  intra-nasal  administration  of  LST-
007 might allow a more rapid targeted delivery 
of  mAb  to  the  lung  compartment  with 
concomitant  establishment  of  therapeutic 
concentrations.         
 
MATERIALS AND METHODS 
 
All  general  chemicals  were  purchased  from 
Sigma,  Rehovot  (Israel).  Bacterial  PA  strains 
were  obtained  from  ATCC  (USA).  NuPAGE 
gels,  associated  buffers,  membranes  and 
Colloidal Blue staining were obtained from In-
Vitrogen  (USA).  Purified  recombinant  PA 
flagellin  type  b  was  expressed  in  pET28 
bacterial  system  and  purified  as  a  histidine-
tagged  protein  using  Nickel  agarose 
chromatography  as  previously  described
7. 
LST-007  was  expressed  in  Chinese  Hamster 
Ovary  (CHO)  cells  and  purified  from  serum-
free  supernatants  using  protein-G  as 
previously described
7.  
 
(i)    Binding  of  BAL  and  blood-containing 
LST-007 samples towards recombinant PA 
flagellin type b in ELISA 
Dilutions of BAL fluid (1:312.5 - 1:40,000) and 
blood (1:20 - 1: 2000) were made and added to 
wells  of  Maxisorp  ELISA  plates  (Nunc,  cat  # 
442404)  pre-coated  with  250  ng  of 
recombinant  PA    flagellin  type  b.  Following 
blocking  overnight  in  PBS-10%  fetal  bovine 
serum,  a  secondary  antibody  consisting  of  a 
1:10,000  dilution  of  goat  anti-human  IgG-Fc-
HRP conjugate (Bethyl, cat # A80-104P) was 
added  for  1  hr  at  room  temperature  and 
colorimetry  performed  following  addition  of 
TMB  solution  (Millipore,  cat  #  ES001).  A 
standard curve of exogenously added LST-007 
(1 pg/ml - 1 µg/ml) was included in all assays.  
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(ii) Binding of BAL fluid containing LST-007 
samples  towards  immobilized,  whole  PA 
bacteria in ELISA 
PAK (flagellin type a), PAO1 (flagellin type b) 
or  PA9721  (aflagellated  strain)  were  grown 
overnight in 5 ml LB at 37
oC and irreversibly 
bound to poly-L-lysine-coated ELISA plates as 
previously  described
7.  BAL  samples  from  15-
240  min  collection  time  points  were  diluted 
1:312.5 - 1:40,000 and taken for fixed ELISA 
and  developed  colorimetrically  following 
addition  of  goat  anti-human  IgG-Fc-HRP 
conjugate.  In  some  experiments,  samples  at 
these time points were normalized to 0.5 µg/ml 
and taken for ELISA. Negative control of BAL 
fluid samples derived from mice injected with 
saline instead of LST-007 was included in all 
assays  and  subtracted  from  absorbances 
obtained with LST-007.  
 
iii) In-vitro PA motility assays 
Motility  studies  using  BAL  samples  diluted  to 
0.1  µg/ml  were  performed  as  previously 
described
7.   
 
iv)  Coomassie  gel  staining  of  BAL-
containing LST-007 samples 
BAL  fluid  samples  from  the  15-240  min  time 
points  were  reduced  with  DTT  (final 
concentration  50 mM),  adjusted  with  4X  LDS 
loading  buffer  and electrophoresed  on  4-12% 
NuPAGE  gels.  Following  removal  of  gel  and 
washing  with  DDW,  the  gel  was  stained  with 
Colloidal Blue according to the manufacturer’s 
recommendations. 
 
v)    Immunoblot  with  BAL  fluid  containing 
LST-007 samples 
200 µl samples of overnight growths of PAK or 
PAO1 were centrifuged, supernatant discarded 
and  pellets  resuspended  in  1X  LDS  sample 
buffer containing 50 mM DTT. Following boiling 
for  10  min  and  a  10  min  centrifugation  at 
10,000  g,  clarified  supernatants  were 
electrophoresed  as  described  above  and 
electroblotted  onto  Nitrocellulose  membrane. 
Membrane strips were prepared and incubated 
with BAL samples at 0.5 µg/ml and taken for 
Enhanced  Chemiluminescence  following 
incubation with a goat anti-human IgG-Fc-HRP 
conjugate.  
 
vi)  In-vivo studies 
Female CD-1 mice, age 10-12 weeks (~ 25 g) 
were  used.  Animal  handling  was    performed 
according  to  the  National    Institute  of  Health 
(NIH) and the Association for Assessment and 
Accreditation  of    Laboratory  Animal  Care 
(AAALAC).  During  acclimation  (5  days)  and 
following LST-007 dosing, mice were housed in 
a  specific  pathogen-free  environment  with  3 
mice  per  cage,  in  polypropylene  cages  fitted 
with  solid  bottoms  and  filled  with  autoclaved 
sawdust  as  bedding  material.  Animals    were 
provided  ad  libitum  with  a  commercial  rodent 
diet and had free access to autoclaved drinking 
water  supplied  to  each  cage.  Automatically 
controlled environment conditions were set to 
maintain a temperature of 22-25ºC with a 12 hr 
light /12 hr dark cycle and air changes in the 
study  room.  LST-007  was  prepared  at  a 
concentration of 2.5 mg/ml following dilution of 
stock antibody with sterile PBS. A total volume 
of 50 µl
8 was applied to both nares as follows: 
25 µl for one naris, a minute delay and then 
application  of  the  second  25  µl  dose  to  the 
contralateral naris. Final dosing was therefore 
2.5 mg/kg. A total of 15 mice were taken for 
simultaneous  PK  sampling  from  bleeds  and 
Bronchoalveolar  Lavage  (BAL)  fluid,  with  3 
mice dedicated each to the 15, 60 and 240 min 
time points and an additional 3 mice dedicated 
for  sampling  at  240  min  following  intra-nasal 
administration of equivalent volumes of sterile 
PBS. At the designated time points, mice were 
anesthetized  by  i.p.    injection  of  85  mg/kg 
Xylazine  and  5  mg/kg  Ketamine  and  bled,  ~ 
500  µl from  the  orbital  sinus.  The  blood  was 
collected  into  1.5  ml  eppendorf  tubes, 
centrifuged and the upper sera layer aliquoted 
and  stored  at  -80
oC  until  required.  While  the 
mice  were  still  under  anesthesia,  they  were 
placed on their backs and airway exposed for 
collection  of  BAL  fluid  by  connection  of  a 
veinflow  to  the  airway  attached  to  a  26G 
needle and 1 ml syringe. A total volume of 1.2 Int J Pharm Bio Sci 2013 Jan; 4(1): (P) 713 - 721 
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ml  of  saline  was  used  to  wash  the  lungs  2 
times with a return BAL volume of ~ 2 ml per 
mouse.  Following  centrifugation,  the  clarified 
BAL supernatant was removed, aliquoted and 
stored at -80 ºC until assay. 
 
RESULTS 
 
Graph 1 
Kinetics of LST-007 appearance in BAL fluid samples and blood. 
 
 
 
Figure 1 
Time-course of LST-007 (µg/ml) concentrations in BAL fluid and plasma in mice 
following intra-nasal administration of LST-007 (5 mg/kg). 
 
Samples of BAL fluid and blood were taken for quantification of LST-007 at 15-240 min following 
intra-nasal administration of the mAb (Fig 1). Concentrations in BAL fluid decreased from 66 µg/ml at 
15 min post-administration to 3 µg/ml at 240 min. In marked contrast, concentrations in plasma were 
extremely low, increasing from 0.1 µg/ml at 15 min to 0.26 µg/ml at 240 min (Fig 1). Since 125 µg 
LST-007 was administered intra-nasally to each mouse, the total amount of mAb present in ~ 2 ml 
BAL fluid was quantified, enabling % bioavailability to be determined at each time point (Table 1, 
parantheses).To that end, at time points of 15, 60 and 240 min, the amount of LST-007 present in 
BAL fluid per mouse was calculated to be 22 µg, 16 µg and 6 µg (Table 1).   
 
Table 1 
Concentrations and amount of LST-007 in BAL fluid following intra-nasal  
administration of  LST-007 (5 mg/kg) to mice 
 
LST -007 (µg/ml) per mouse
  15 min 60 min 240 min
BAL 11 (22 µg) 8 (16 µg) 3 (6 µg)
Sera 0.1 0.15 0.26
 
Coomassie gel staining of BAL fluid samples containing LST-007 
 
Fifteen µl samples of LST-007 in BAL fluid from time points 15 min (Fig 2, lane A), 60 min (Fig 2, lane 
B) and 240 min (Fig 2, lane C) were electrophoresed on a protein gel and stained with Coomassie Int J Pharm Bio Sci 2013 Jan; 4(1): (P) 713 - 721 
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Blue. A control lane D, consisting of 5 µg LST-007 was included as a positive control. All lanes 
demonstrated the presence of heavy and light mAb chains with no evidence of degraded products.  
 
 
 
Figure 2 
Coomassie-gel staining of reduced LST-007 in BAL fluid samples harvested at 15 min (lane A), 
60 min (lane B) and 240 min (lane C). Lane D represents 5 µg of control LST-007.  Upper band 
denotes 50 kD and lower band 25 kD, corresponding to VH and VL chains respectively. 
 
Graph 2 
Binding of BAL fluid containing LST-007 towards immobilized PAO1 in ELISA 
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Figure 2 
Binding of BAL fluid containing LST-007 towards immobilized PAO1 in ELISA.  BAL fluid 
samples collected from time points 15 min (circles), 60 min (squares) and 240 min (triangles) 
were diluted 312.5 to 40,000 and taken for binding to PAO1 followed by colorimetric 
development via a secondary anti-human detecting antibody. 
 
In addition to the standard ELISA employing recombinant PA flagellin type b to quantify binding of 
BAL-containing  LST-007  samples  (Fig  1),  these  same  samples  were  taken  for  binding  towards 
immobilized PAO1 bacteria
7.  In these studies, BAL samples harvested at time points 15-240 min 
following intra-nasal administration of LST-007, demonstrated specific binding towards PAO1 which 
decreased on dilution from 312.5 - 40,000 (Fig 2).  Binding of all BAL samples to PAK (flagellin type 
a) or PA9721, a non-flagellated PA bacterium were negligible (data not shown).  
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Graph 3 
Binding of normalized LST-007 (0.5 µg/ml) from BAL fluid samples harvested at 15 - 240 min 
following intra-nasal administration of LST-007 and immunoreactivities 
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Figure 3 
LST-007 in all BAL fluid samples was adjusted to 0.5 µg/ml and taken for binding towards PAO1 by 
ELISA.  Inset Immunoreactive properties of LST-007 in BAL fluid samples towards PAO1 lysates. Lanes 
1 and 2 demonstrate specificity of binding of control LST-007 (0.5 µg/ml) towards PAO1 (lane 1) but not 
PAK (lane 2). LST-007 (0.5 µg/ml) in BAL fluid samples from 15 min (lane 3), 60 min (lane 4) and 240 min 
(lane 5) all bound PAO1. (Mw of immunoreactive band = 52 kD).  
 
Table 2 
Bioactivities of BAL-fluid containing LST-007 as measured by inhibition of PAO1 motility in 
soft agar assays 
 
BAL harvest time (min) Halo diameter 
(mm)
% inhibition of 
PAO1 motility 
15 2 83
60 3 75
240 4 67
Exogenous LST-007 2 83
Exogenous human isotype mAb 12 0
 
LST-007 in BAL fluid samples were added to soft agar at a final concentration of   0.1 µg/ml  and their abilities to impede PAO1 motility 
measured as previously described
7. All samples inhibited PAO1 motility by 67-83% (Table 2), an effect similarly observed with exogenously 
added LST-007 (0.1 µg/ml) but not a human isotype control mAb.  
 
DISCUSSION 
 
The  development  of  anti-PA  mAbs  targeting 
virulence factors such as 011 LPS
9, PcrV
10 and 
flagella
7  represents  a  highly  promising  and 
innovative  therapeutic  approach  to  support 
antibiotic  therapies  and  have  already  yielded 
highly promising clinical data
9,10.  Recently, we 
reported
7    the  parenteral,  pre-clinical 
therapeutic effect of a fully human anti-flagellin 
type b mAb termed LST-007, as demonstrated 
by its capability to improve  animal survival (60-Int J Pharm Bio Sci 2013 Jan; 4(1): (P) 713 - 721 
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75%)  in  a  lethal  mouse  model  of  pneumonia 
driven  by  a  MDR  PA  strain.  LST-007’s 
beneficial effect was purported to be, at least in 
part,  due  to  its  ability  to  impede  bacterial 
motility at concentrations similar to LST-007’s 
KD  towards  PA  flagellin  type  b
7.  In  follow-up 
preliminary  efficacy  studies,  prophylactic  i.v. 
LST-007  (given  24  hr  prior  to  PA  infection) 
permitted 100% animal survival (Adawi et al, in 
preparation). This  effect  was  presumably  due 
to the 24 hr time period required for      LST-
007  to  attain  optimal  concentrations  in  BAL 
fluid
7.  Thus,  the  present  study  aimed  to 
evaluate  if  intra-nasal  administration  might 
permit  a  more  rapid  delivery  of  LST-007  into 
the  lung  compartment  and  achieve 
therapeutically-relevant  concentrations.   
Interestingly, intra-nasal administration of LST-
007  (5  mg/kg)  resulted  in  a  highly  efficient 
delivery to the lung compartment within 15-60 
min  post-administration  with  calculated 
bioavailabilities  of  ~  20%  and  13% 
respectively. Examination of BAL fluid samples 
containing  LST-007  demonstrated  the 
presence of intact antibody by Coomassie gel 
staining,  dilution-dependent  recognition  of 
recombinant PA flagellin type b (ELISA) as well 
as avid binding towards PAO1 bacteria using 
whole  cell  (ELISA)  and  lysate  preparations 
(immunoblot).    Additionally,  normalization  of 
LST-007 (0.1 µg/ml) in BAL fluid samples from 
all time points were highly effective in blunting 
PAO1 motility in soft agar assays, confirming 
our  previous  findings
7.    The  minimal 
concentrations  of  LST-007  observed  in  blood 
throughout the 4 hr time course would confirm 
the  capability  of  intra-nasal  administration  to 
essentially  target  delivery  of  the  mAb  to  the 
lung  compartment.  MAbs
11  represent  the 
fastest  growing  class  of  therapeutics  with 
currently ~ 35 products approved and 100’s in 
various  stages  of  clinical  development.  The 
flexibility  of  therapeutic  mAbs  is  underscored 
by accumulating data that their formulation and 
mode of administration can be fine-tuned in an 
effort  to  permit  a more  targeted  delivery.  For 
example,  intra-nasal  administration  of 
cetuximab has been evaluated clinically in  
 
hereditary  hemorrhagic  telangiectasia  with 
improved,  short-term  benefit
12.  Furthermore, 
promising  pre-clinical  reports  have  described 
inhalation  delivery  of  cetuximab  to  treat  lung 
tumors
13, nebulized anti-IL-13 FAb fragment to 
treat  asthma
14,  intra-nasal  administration  of 
nanobodies  that  effectively  target  RSV
15  and 
H5N1
16  influenza  virus  and  similar 
administration  of  an  IgM  to  prevent 
Pneumocystis carnii pneumonia
17.  In the case 
of hospital-associated pneumonias caused by 
PA,  understanding  the  modified  PK/PD 
“setting” is critical for successful anti-microbial 
therapy
18.  To  that  end,  targeted  delivery  of 
innovative  therapeutics  (eg.  anti-virulence 
mAbs) or even existing antibiotics to the lung 
compartment  would  clearly  be  advantageous 
since it would allow a rapid and much desired 
establishment  of  achievable  therapeutics 
concentrations at presumed reduced dosing as 
compared to parenteral routes. The data herein 
describing the effective lung delivery of a novel 
anti-infective  PA  mAb    following  intra-nasal 
administration,  support  the  rationale  to 
investigate if this mode of delivery or follow-up 
inhalation  approaches  can  combat  lethal  and 
chronic PA infections in pre-clinical models of 
pneumonia.  Positive  findings  would 
undoubtedly  further  drive  LST-007’s  clinical 
development  and  provide  a  basis  for  the 
development  of  additional  monospecific  anti-
flagella mAbs (eg. targeting flagellin type a) or 
even  bispecific  mAbs  harboring  binding  sites 
for flagellin type a and b. 
 
CONCLUSION 
 
Intra-nasal administration of LST-007, a highly 
novel anti-PA mAb targeting PA flagella type b, 
resulted  in  a  targeted  delivery  to  the  lung 
compartment  achieving  concentrations  in 
excess of those required to impede PA motility. 
Such  a  mode  of  administration  or  even 
inhalation  technologies  could  be  highly 
beneficial  to  patients  suffering  from  life-
threatening  nosocomial  infections  caused  by 
PA. 
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